Tourmaline Bio forms Cardiovascular Scientific Advisory Board

Tourmaline Bio announced the formation of its Cardiovascular Scientific Advisory Board. The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025. The CV SAB brings together academic and industry veterans with significant experience in cardiovascular medicine, clinical trial design and execution, and therapeutic innovation. Their insights and guidance are expected to be instrumental in shaping the strategic direction of Tourmaline’s cardiovascular program as the company prepares for Phase 3 clinical trial readiness in 2025, supporting efforts to redefine standards of care for high-risk cardiovascular disease patients. Cardiovascular Scientific Advisory Board Members: Joshua Beckman, MD, MSc – UT Southwestern Medical Center; Marc Bonaca, MD, MPH – University of Colorado, CPC Clinical Research; Robin Choudhury, MA, DM, FRCP – University of Oxford; Douglas L. Mann, MD – Washington University School of Medicine; James Min, MD – Cleerly, Inc.; Pradeep Natarajan, MD, MMSc – Massachusetts General Hospital; Michael D. Shapiro, DO, MCR – Wake Forest University School of Medicine; Michael Szarek, PhD – University of Colorado, CPC Clinical Research.